查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848002

兽用抗菌药物敏感性检测市场按检测类型、动物类型、最终用户、病原体类型、样品类型和产品类型划分－2025-2032年全球预测

Veterinary Antimicrobial Susceptibility Testing Market by Test Type, Animal Type, End User, Pathogen Type, Sample Type, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽用抗菌药物敏感性测试市场规模将达到 2.2188 亿美元，复合年增长率为 8.75%。

主要市场统计数据
基准年 2024 1.1338亿美元
预计年份：2025年 1.2333亿美元
预测年份：2032年 2.2188亿美元
复合年增长率 (%) 8.75%

将兽用抗菌药物敏感性检测置于临床实践、实验室操作和更广泛的「同一健康」理念框架下进行考虑，以指导及时、负责任的干预措施。

兽医学中抗菌药物抗药性的演变迫切需要实证医学的指导，以阐明诊断检测在维持治疗效果、保护动物和公众健康方面的作用。兽医抗菌药物敏感性检测处于临床决策、监测和监管的交汇点，其有效应用会影响治疗结果、抗菌药物管理计划以及新出现的抗药性机制的检测。随着诊断能力的进步，实验室和临床医生必须采用能够在临床上可接受的时限内提供可靠且可重复结果的工作流程和技术。

这种实践转变体现了兽医实践的异质性，涵盖了从服务于畜牧业的高性能诊断实验室到伴侣动物诊所和水产养殖场的照护现场检测。动物类型生物学、样本基质和病原体多样性的差异带来了独特的分析挑战，需要量身定制的方法和解读标准。因此，实验室主任和政策制定者在选择检测平台和通讯协定时，必须权衡准确性、週转时间、成本和法规遵循。

此外，分子方法与表型检测的结合正在显着改变诊断管道。虽然传统的肉汤微量稀释法和纸锭扩散法仍然是解读表型药敏感性的临床标准，但分子方法能够快速检测抗药性决定簇和与疫情相关的基因型。这种应用凸显了兽医、微生物学家、流行病学家和产业伙伴之间进行多学科合作的迫切需要，以便将诊断创新转化为抗菌药物管理和动物健康的持续改进。

技术创新、监管演变和数位整合如何重塑兽医易感性检测并加速临床和监测能力的发展

兽医抗菌药物敏感性检测的变革性转变反映了技术创新、监管预期变化以及不断发展的临床需求，这些因素共同重塑了诊断流程。自动化系统提高了检测通量和标准化程度，使实验室能够在扩大营运规模的同时，降低药敏结果判读的差异性。同时，快速分子技术和新一代定序技术拓展了我们检测抗药性决定因素和追踪传播途径的能力，提高了监测能力，并为有针对性的干预措施提供了依据。

数据管理软体和整合资讯平台支援一致的解读、报告和长期监测。这些工具有助于汇总不同地点和物种的药敏数据，从而加强区域和国家层面的抗菌药物管理工作。同时，监管机构和专业学会正在提供更完善的解读和验证标准指南，要求实验室重新评估其工作流程，并确保符合不断发展的品质框架。

经济和营运压力正在推动市场行为的转变。终端用户要求解决方案能够兼顾准确性、速度和成本效益，促使产品种类日益丰富，包括自动化仪器、桌上型系统和模组化试剂套件。因此，製造商和服务供应商越来越注重互通性、远端支援以及能够满足兽医检测环境实际需求的客製化试剂系统。这些转变共同推动着一个更互联、反应迅速的诊断生态系统的形成，从而能够同时支持临床诊疗和公共卫生目标。

评估2025年关税调整对诊断设备、耗材和实验室供应链韧性的营运和采购影响

2025年生效的关税调整为国际诊断设备、耗材和试剂采购领域的相关人员带来了新的挑战。部分进口检测设备和组件关税的提高，造成了成本压力，影响兽医诊断实验室、设备製造商和耗材经销商的筹资策略。这种不断变化的经济环境迫使检测机构重新评估供应商关係、库存策略和资本支出计划，以减轻短期预算影响。

为此，多家检测实验室和终端用户正尽可能优先选择在地采购，实现供应链多元化，并与区域製造商合作，以减轻关税波动的影响。这加速了关于区域製造能力以及关键耗材（例如肉汤微量稀释板、纸片扩散法耗材和分子检测试剂）本地化的讨论。同时，采购团队正在评估包括物流、清关和潜在延误在内的总拥有成本，并将这些成本纳入采购週期和服务等级协议中。

在供应商方面，製造商正在探索各种策略性应对措施以维持市场进入，例如部分本地化生产、价格回扣和配套服务。这些措施旨在透过最大限度地减少直接成本转嫁给最终用户，从而维持自动化系统和分子平台的普及率。值得注意的是，关税环境凸显了在检测设施采购流程中建立更完善的风险评估框架的必要性，强调製定应急计划和采取协作方式，以在应对财务限制的同时保障研究的连续性。

揭示检测方式、物种特定需求、最终用户、病原体多样性、样本基质和产品类型如何共同决定诊断优先事项和投资策略。

细分市场层面的动态揭示了不同的检测方式、动物群、终端用户、病原体组、样本基质和产品类型如何影响诊断需求和创新重点。检测类型分为自动化系统、肉汤微量稀释法、纸锭扩散法、ETEST 和分子检测法，其中自动化检测又根据平台进一步细分，包括 MicroScan、PHOENIX、VITEK 和 WalkAway 系统。肉汤微量稀释法分为自动化和手动两种形式，分子检测包括基于 LAMP 的方法、基于 NGS 的策略、PCR 和 qPCR，每种方法在速度、灵敏度和资讯深度之间各有优劣。

涵盖的动物类型包括水产养殖动物、伴侣动物、马匹、牲畜和家禽，重点阐述了疾病流行率、饲养方式和法律规范在不同动物类型中的差异，以及这些差异如何影响检测流程。最终用户涵盖製药和生物技术公司、研究机构、动物诊断实验室以及兽医医院和诊所，每个相关人员都有其独特的优先事项：製药开发商重视用于药物开发的标准化药敏试验数据；研究机构专注于检测方法开发和流行病学研究；诊断实验室优先考虑检测通量和品管；而临床机构则需要快速、可操作的结果。

病原体类型分为真菌、革兰氏阴性菌、革兰氏阳性菌和分枝桿菌，每种病原体都需要不同的检测组合、判读标准和隔离方法。检体类型，例如血液、牛奶、检体、组织和尿液，会带来不同的分析前挑战，影响检测方法的选择和验证的必要性。产品类型涵盖仪器、试剂套件和软体服务。仪器进一步分为自动化系统和桌上型系统，试剂套件分为耗材和试剂，软体服务分为资料管理软体和技术支援咨询。这些细分领域的交集导致了不同的投资模式、检验要求和打入市场策略，凸显了模组化产品设计、稳健的供应链和有针对性的客户支援对于满足兽医诊断行业多样化需求的重要性。

区域诊断技术的应用将受到美洲、欧洲、中东和非洲以及亚太地区基础设施、法律规范和特定动物类型优先事项的驱动。

区域模式清晰地表明，地理位置、监管环境和产业基础设施如何影响抗菌药物敏感性检测解决方案的采用。在美洲，先进的实验室网路和成熟的兽医临床实践支持自动化设备和整合资讯技术的早期应用，而区域性倡议则侧重于监测数据汇总和管理项目，将临床实验室与公共卫生系统连接起来。在伴侣动物和畜牧业领域，兽医诊断的投资均有所增加，这主要得益于私人检测实验室的整合以及针对特定行业的监管关注。

在欧洲、中东和非洲，统一的监管环境和实验室认证框架催生了对标准化检测方案和可互通资料系统的需求。北欧和西欧市场正日益采用分子诊断和自动化平台，并辅以完善的监测基础设施；而中东和非洲则优先考虑可扩展、经济高效的解决方案，以应对物流限制和不同养殖系统中物种的多样性。

亚太地区是一个充满活力的地区，这得益于其蓬勃发展的农业产业，製造业产能不断增长，并高度重视水产养殖和畜牧业诊断。部分市场的快速都市化和伴侣动物数量的增加，也推动了对临床级诊断产品的需求。在这些全部区域，跨境贸易、在地化生产以及不断变化的监管要求，迫使製造商和检测实验室采用灵活的分销模式和本地化支援策略，以确保检测品质的稳定性和供应的可靠性。

供应商如何将检验的平台、本地化支援和整合数据分析相结合，以提供可靠的诊断解决方案和建立长期的客户伙伴关係

兽用抗菌药物敏感性检测领域的领导者凭藉其广泛的平台、地理覆盖范围和服务能力脱颖而出，这些优势既能满足常规诊断需求，也能满足复杂的监测要求。检验的自动化仪器与强大的试剂供应链和数据管理软体结合的製造商，能够更好地支援寻求标准化工作流程的高效能实验室。同时，投资于模组化桌上型平台和专用试剂套件的公司，则能更好地满足分散式临床环境和物种特异性检测需求。

提供服务和支援对于维持仪器运作和确保实验室间结果判读的一致性至关重要。技术支援、培训专案和咨询服务能够帮助实验室进行验证、品质保证和法规遵循，从而提高客户维繫并创造长期伙伴关係机会。与研究机构和药物研发公司的合作能够进一步加强产品平臺和新方法的推广，尤其是在应对新出现的抗药性机制方面。

策略差异化也体现在软体和分析能力。能够提供整合数据管理、自动化报告和趋势分析的供应商，可以帮助检测实验室将原始的易感性数据转化为可供临床医生和药物管理委员会使用的实用资讯。利用伙伴关係关係拓展区域生产和分销网络的公司，更有能力应对供应链中断和关税的影响，从而维持市场进入，并确保终端用户能够持续获得检测服务。

供应商和实验室可采取切实可行的策略性倡议，以提升诊断效能、供应韧性和整合资料能力，从而支援管理目标的实现。

产业领导者应优先投资于能够提升诊断准确性、供应链稳定性以及可操作数据工作流程的领域，以满足临床和监测需求。首先，透过提供高通量自动化系统和灵活的桌上型解决方案，使平台组合与终端用户的实际操作相契合，能够帮助供应商应对各种实验室环境和临床情况。此外，配备可靠的套件、试剂和品管材料，可降低采用门槛，并确保不同实验室获得可重复的结果。

其次，扩大区域製造和物流能力可以减轻关税相关的成本波动和地缘政治供应中断的影响。建立区域试剂生产、策略性经销伙伴和库存缓衝策略有助于确保检测服务的连续性。第三，投资资料管理软体和互通性，透过实现整合报告、趋势分析和资料共用，增强了对最终用户的价值提案，从而更好地进行管理和监督。这种方法不仅有助于加强与检测机构和相关人员的联繫，还能创造与分析和咨询服务相关的新收入来源。

最后，产业相关人员应深化与监管机构、专业协会和兽医网路的合作，以统一检测方法验证、解读标准和报告规范。积极合作将加速创新方法的应用，确保符合不断更新的指南，并支持将诊断数据转化为有效的管理政策。综上所述，这些建议支持一项平衡的策略，该策略强调技术卓越、营运韧性和相关人员合作，以促进永续发展。

采用混合方法，结合专家访谈、技术文献综述和产品格局分析，以提供可操作且经过严格检验的诊断见解。

本研究采用多维度的二级调查方法，结合了对产业专家的质性访谈、文献综述和产品格局分析，旨在全面了解兽用抗菌药物敏感性检测环境。主要研究内容包括与实验室主任、临床兽医、采购专家和行业高管进行结构化访谈，以了解营运重点、验证实践和采购行为。这些访谈着重于洞察实际工作流程以及实验室在速度、准确性和成本之间权衡取舍。

二次研究查阅了同行评审的科学出版物、监管指导文件和公共监测报告，以确保在说明方法、解释标准和病原体特异性检测注意事项方面具有技术准确性。产品格局分析对仪器平台、检测形式、试剂系统和软体进行了分类，并绘製了功能和服务模式图。研究过程中，始终关注验证要求、品管措施以及不同司法管辖区法律规范的影响。

数据综合分析结合了定性研究结果、产品分析和区域分析，以识别关键趋势、营运挑战和策略机会。透过整合来自多个相关人员的观点，并评估其与已记录的监管动态和同侪审查证据的一致性，实现了对洞察结果的交叉检验。这种混合方法确保了结论既能反映实际情况，又能体现技术严谨性，同时也能为产业、临床和政策领域的决策者提供切实可行的指导。

摘要了综合诊断、弹性供应链和相关人员协作将如何定义下一阶段的兽用抗菌药物管理和有效性检测。

总之，兽用抗菌药物敏感性检测正处于曲折点，其特点是技术进步、采购动态变化以及对数据主导管理的日益增长的期望。表型和分子方法的并存为改进临床决策和监测提供了互补的管道，而数位整合则增强了将孤立的检测结果转化为纵向资讯的能力。然而，与样本变异性、物种特异性验证和供应链脆弱性相关的挑战仍然突出，需要製造商、检测实验室和政策制定者共同应对。

未来的成功取决于务实的策略，这些策略需要将产品创新与不同兽医环境的营运实际情况结合。加强在地化生产、改进技术支援以及实施可互通的软体解决方案，将减少终端用户的摩擦，并在面临财务和物流压力时保障检测的连续性。同样重要的是，相关人员应携手合作，协调验证标准，并确保诊断结果能够转化为有效的抗菌药物管理措施，从而保护动物和公众健康。

最终，诊断界有机会透过优先考虑准确性、可近性和可操作的数据流，在治疗效果和抗药性抑制方面取得可衡量的进展。如此一来，相关人员便能确保抗菌药物的长期有效性，并支持能够有效应对不断演变的微生物威胁的、具有韧性的动物健康系统。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将快速分子诊断技术整合到农场兽医药敏试验工作流程中，以缩短週转时间
  • 推出一款可携式照护现场（POC​​）抗菌药物敏感性检测设备，用于偏远农场的牲畜健康管理
  • 开发专门针对临床环境中兽医细菌分离株的自动化、高性能表型药敏试验平台
  • 实施人工智慧驱动的预测分析工具，以监测动物健康领域抗菌素抗药性的趋势
  • 扩展多重PCR检测板，用于同时检测和定量伴侣动物病原体中的多种抗药性基因
  • 基于农场特定药敏试验数据的个人化抗菌药物管理方案的出现，旨在遏制兽用抗生素的滥用。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测类型分類的动物抗菌药物敏感性检测市场

  • 自动化系统
    • 微型扫描系统
    • 凤凰系统
    • VITEK系统
    • 离开系统
  • 肉汤微量稀释法
    • 自动培养基微量稀释
    • 手动肉汤微量稀释法
  • 纸锭扩散法
  • ETEST
  • 分子方法
    • 基于LAMP的方法
    • 基于NGS的方法
    • 基于PCR的方法
    • 基于qPCR的方法

9. 依动物类型分類的动物抗菌药物敏感性测试市场

  • 水产养殖
  • 伴侣动物
  • 马
  • 家畜
  • 家禽

第十章 以最终用户分類的动物抗菌药物敏感性测试市场

  • 製药和生物技术
  • 研究所
  • 兽医诊断实验室
  • 兽医医院和诊所

第十一章 依病原体类型分類的动物抗菌药物敏感性测试市场

  • 真菌
  • 革兰氏阴性菌
  • 革兰氏阳性菌
  • 结核分枝桿菌

第十二章：按样本类型分類的动物抗菌药物敏感性测试市场

  • 血
  • 牛奶
  • 棉花棒
  • 组织
  • 尿

第十三章 动物抗菌药物敏感性测试市场（依产品类型划分）

  • 装置
    • 自动化设备
    • 桌面设备
  • 套件和试剂
    • 消耗品
    • 试剂
  • 软体和服务
    • 资料管理软体
    • 技术支援和咨询

14. 各地区兽用抗菌药物敏感性检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 动物抗菌药物敏感性测试市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国动物抗菌药物敏感性测试市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Becton, Dickinson and Company
    • IDEXX Laboratories, Inc.
    • Bruker Corporation
    • Creative Diagnostics
    • Merck & Co., Inc.
    • Eurofins Scientific SE
    • SGS SA
    • Bio-Rad Laboratories
Product Code: MRR-FD3F12D533B4

The Veterinary Antimicrobial Susceptibility Testing Market is projected to grow by USD 221.88 million at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 113.38 million
Estimated Year [2025] USD 123.33 million
Forecast Year [2032] USD 221.88 million
CAGR (%) 8.75%

Contextualizing veterinary antimicrobial susceptibility testing within clinical practice, laboratory operations, and the broader One Health imperative to guide timely and responsible interventions

The evolution of antimicrobial resistance in animal health demands a clear, evidence-driven introduction that frames the role of diagnostic testing in preserving therapeutic efficacy and safeguarding both animal and public health. Veterinary antimicrobial susceptibility testing operates at the intersection of clinical decision-making, surveillance, and regulatory oversight, and its effective deployment influences treatment outcomes, antimicrobial stewardship programs, and the detection of emerging resistance mechanisms. As diagnostic capabilities advance, laboratories and clinicians must adopt workflows and technologies that deliver reliable, reproducible results within clinically actionable timeframes.

The introduction to this landscape recognizes the heterogeneity of veterinary practice, from high-throughput diagnostic laboratories servicing livestock operations to point-of-care testing in companion animal clinics and aquaculture settings. Differences in species biology, sample matrices, and pathogen diversity create unique analytical challenges that require tailored methodologies and interpretive criteria. Consequently, laboratory directors and policy-makers must balance considerations of accuracy, turnaround time, cost, and regulatory compliance when selecting testing platforms and protocols.

Moreover, the integration of molecular methods alongside phenotypic assays has reshaped diagnostic pathways. Molecular approaches enable rapid detection of resistance determinants and outbreak-related genotypes, while traditional broth microdilution and disk diffusion remain the clinical standards for phenotypic susceptibility interpretation. This introduction underscores the imperative for cross-disciplinary collaboration among veterinarians, microbiologists, epidemiologists, and industry partners to translate diagnostic innovation into sustained improvements in antimicrobial stewardship and animal health outcomes.

How technological innovation, regulatory evolution, and digital integration are reshaping veterinary susceptibility testing and accelerating clinical and surveillance capabilities

Transformative shifts in veterinary antimicrobial susceptibility testing reflect technological innovation, shifting regulatory expectations, and evolving clinical needs that together are redefining diagnostic pathways. Automated systems are improving throughput and standardization, enabling laboratories to scale operations while reducing variability in susceptibility interpretation. Concurrently, rapid molecular techniques and next-generation sequencing are expanding the ability to detect resistance determinants and trace transmission, thus enhancing surveillance capacity and informing targeted interventions.

Industry adoption is further influenced by digital transformation, with data management software and integrated informatics platforms supporting interpretive consistency, reporting, and longitudinal surveillance. These tools facilitate the aggregation of susceptibility data across facilities and species, which strengthens regional and national antimicrobial stewardship initiatives. At the same time, regulatory bodies and professional societies are intensifying guidance on interpretive criteria and validation standards, prompting laboratories to re-evaluate workflows and ensure compliance with evolving quality frameworks.

Economic and operational pressures are catalyzing changes in market behavior. End users demand solutions that balance accuracy and speed with cost-effectiveness, leading to a diversification of offerings across automated instruments, bench-top systems, and modular kits. As a result, manufacturers and service providers are increasingly focused on interoperability, remote support, and tailored reagent systems that address the practical realities of veterinary testing environments. Together, these shifts are driving a more connected, responsive diagnostic ecosystem capable of supporting both clinical care and public health objectives.

Assessing the operational and procurement consequences of 2025 tariff adjustments on diagnostic equipment, consumables, and laboratory supply chain resilience

Tariff changes enacted in 2025 have introduced a new layer of complexity for stakeholders procuring diagnostic instruments, consumables, and reagents internationally. Increased duties on certain imported laboratory equipment and components have created cost pressures that affect procurement strategies for veterinary diagnostic laboratories, manufacturers of instruments, and distributors of consumables. These fiscal shifts have prompted organizations to reassess supplier relationships, inventory strategies, and capital investment timelines to mitigate near-term budgetary impacts.

In response, several laboratories and end users are prioritizing local sourcing where feasible, engaging with regional manufacturers to diversify supply chains and reduce exposure to tariff volatility. This has accelerated conversations around regional manufacturing capacity and the localization of critical consumables such as broth microdilution panels, disk diffusion supplies, and molecular assay reagents. Simultaneously, procurement teams are evaluating total cost of ownership, including logistics, customs processing, and potential delays, to inform purchasing cycles and service-level agreements.

On the supplier side, manufacturers are exploring strategic responses that include partial regional manufacturing, pricing rebates, and bundled service offerings to preserve market access. These adaptations aim to sustain adoption rates of automated systems and molecular platforms by minimizing direct cost pass-throughs to end users. Importantly, the tariff environment has highlighted the need for more robust risk assessment frameworks within laboratory procurement processes, emphasizing contingency planning and collaborative approaches that protect testing continuity while managing fiscal constraints.

Dissecting how test modalities, species-specific needs, end users, pathogen diversity, sample matrices, and product categories converge to define diagnostic priorities and investment strategies

Segment-level dynamics illuminate how different test modalities, animal populations, end users, pathogen groups, sample matrices, and product categories shape diagnostic demand and innovation priorities. Test type distinctions span Automated Systems, Broth Microdilution, Disk Diffusion, Etest, and Molecular Methods, with Automated Systems further differentiated by platforms such as MicroScan, PHOENIX, VITEK, and WalkAway systems. Broth microdilution is bifurcated into automated and manual formats, while molecular modalities encompass LAMP-based methods, NGS-based strategies, PCR, and qPCR, each offering distinct trade-offs between speed, sensitivity, and informational depth.

Animal type segmentation covers aquaculture, companion animals, equine, livestock, and poultry, highlighting how disease prevalence, husbandry practices, and regulatory frameworks vary across species and influence testing workflows. End users range from pharmaceutical and biotech companies to research institutes, veterinary diagnostic laboratories, and veterinary hospitals and clinics, and each of these stakeholders exhibits unique priorities: pharmaceutical developers emphasize standardized AST data for drug development, research institutes focus on method development and epidemiology, diagnostic laboratories prioritize throughput and quality control, and clinical settings require rapid, actionable results.

Pathogen type divides into fungi, Gram-negative bacteria, Gram-positive bacteria, and mycobacteria, which necessitates distinct panels, interpretive criteria, and containment practices. Sample types such as blood, milk, swab specimens, tissue, and urine impose diverse pre-analytical challenges that influence assay selection and validation needs. Product-type segmentation spans instruments, kits and reagents, and software and services; instruments are further categorized into automated and bench-top systems, kits and reagents into consumables and reagents, and software and services into data management software and technical support and consulting. These intersecting segments drive differential investment patterns, validation requirements, and market entry strategies, and they underscore the importance of modular product design, robust supply chains, and targeted customer support to meet the varied demands of the veterinary diagnostic community.

Regional diagnostic adoption is driven by infrastructure, regulatory frameworks, and species-specific priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Regional patterns underscore how geography, regulatory context, and industry infrastructure shape adoption of antimicrobial susceptibility testing solutions. In the Americas, advanced laboratory networks and established veterinary clinical practices support early adoption of automated instruments and integrated informatics, while regional initiatives emphasize surveillance data aggregation and stewardship programs that connect clinical laboratories with public health systems. Investment in veterinary diagnostics is visible across companion animal and livestock sectors, driven by a combination of private laboratory consolidation and sector-specific regulatory attention.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts and laboratory accreditation frameworks are generating demand for standardized testing protocols and interoperable data systems. Northern and Western European markets exhibit high uptake of molecular diagnostics and automated platforms, supported by robust surveillance infrastructures, whereas other subregions focus on capacity building and access to reliable consumables. Meanwhile, the Middle East and Africa are prioritizing scalable, cost-effective solutions that address logistical constraints and species diversity across varying husbandry systems.

Asia-Pacific remains a dynamic region with growing manufacturing capabilities and a strong emphasis on aquaculture and livestock diagnostics, reflecting the region's agricultural footprint. Rapid urbanization and rising companion animal ownership in certain markets are creating parallel demand for clinical-grade diagnostics. Across these regions, cross-border trade, regional manufacturing, and evolving regulatory requirements are prompting manufacturers and laboratories to adopt flexible distribution models and localized support strategies to ensure consistent testing quality and supply reliability.

How vendors are combining validated platforms, localized support, and integrated data analytics to deliver resilient diagnostic solutions and long-term customer partnerships

Leading organizations in the veterinary antimicrobial susceptibility testing space are differentiating through platform breadth, regional reach, and service capabilities that address both routine diagnostic needs and complex surveillance requirements. Manufacturers that combine validated automated instruments with robust reagent supply chains and data management software have an advantage in supporting high-throughput laboratories seeking to standardize workflows. At the same time, companies that invest in modular bench-top platforms and specialized kits are well positioned to serve decentralized clinical settings and species-specific testing demands.

Service and support offerings play a critical role in maintaining instrument uptime and ensuring interpretive consistency across sites. Technical support, training programs, and consulting services that assist laboratories with validation, quality assurance, and regulatory compliance enhance customer retention and create opportunities for long-term partnerships. Collaborative engagements with research institutes and pharmaceutical developers further strengthen product pipelines and phase-in of new methodologies, especially for emerging resistance mechanisms.

Strategic differentiation also extends to software and analytics capabilities. Providers that enable integrated data management, automated reporting, and trend analysis help laboratories convert raw susceptibility data into actionable intelligence for clinicians and stewardship committees. Companies leveraging partnerships to expand regional manufacturing and distribution networks are better equipped to respond to supply chain disruptions and tariff impacts, thereby preserving market access and supporting consistent testing availability for end users.

Practical strategic moves for vendors and laboratories to strengthen diagnostic performance, supply resilience, and integrated data capabilities in support of stewardship objectives

Industry leaders should prioritize investments that strengthen diagnostic accuracy, supply resilience, and actionable data workflows to meet clinical and surveillance needs. First, aligning platform portfolios with end-user operational realities-by offering both high-throughput automated systems and flexible bench-top solutions-will allow providers to serve the full spectrum of laboratory environments and clinical contexts. Complementing hardware with reliable kits, reagents, and quality control materials reduces barriers to adoption and supports reproducible results across sites.

Second, expanding regional manufacturing and logistics capabilities will mitigate exposure to tariff-related cost volatility and geopolitical supply disruptions. Establishing localized reagent production, strategic distribution partnerships, and inventory buffering strategies will protect continuity of testing services. Third, investing in data management software and interoperability increases the value proposition for end users by enabling integrated reporting, trend analysis, and data sharing for stewardship and surveillance purposes. This approach fosters stronger ties with laboratories and policy stakeholders while creating new revenue streams linked to analytics and advisory services.

Finally, industry players should deepen engagement with regulators, professional societies, and veterinary networks to align assay validation, interpretive criteria, and reporting standards. Proactive collaboration will accelerate adoption of innovative methods, ensure compliance with evolving guidelines, and support the translation of diagnostic data into effective stewardship policies. Collectively, these recommendations encourage a balanced strategy that emphasizes technological excellence, operational resilience, and stakeholder collaboration to drive sustainable outcomes.

A mixed-methods approach combining expert interviews, technical literature review, and product landscape analysis to produce actionable and rigorously validated diagnostic insights

This research synthesis draws on a multidimensional methodology that combines primary qualitative engagement with domain experts, secondary literature review, and product landscape analysis to build a comprehensive understanding of the veterinary antimicrobial susceptibility testing environment. Primary inputs include structured interviews with laboratory directors, clinical veterinarians, procurement specialists, and industry executives to capture operational priorities, validation practices, and procurement behaviors. These conversations prioritize insights into real-world workflows and the practical trade-offs laboratories make between speed, accuracy, and cost.

Secondary research canvassed peer-reviewed scientific publications, regulatory guidance documents, and public surveillance reports to ensure technical accuracy in describing methodologies, interpretive criteria, and pathogen-specific testing considerations. Product landscape analysis involved cataloging instrument platforms, assay formats, reagent systems, and software offerings to map functional capabilities and service models. Throughout, attention was paid to validation requirements, quality management practices, and the implications of regulatory frameworks across jurisdictions.

Data synthesis integrated qualitative findings with product and regional analyses to identify key trends, operational challenges, and strategic opportunities. Cross-validation of insights was achieved by triangulating perspectives from multiple stakeholder groups and by assessing consistency with documented regulatory developments and peer-reviewed evidence. This mixed-methods approach ensures that conclusions reflect practical realities and technical rigor while remaining actionable for decision-makers across industry, clinical, and policy domains.

Summarizing how integrated diagnostics, resilient supply chains, and stakeholder collaboration will define the next phase of veterinary antimicrobial stewardship and testing effectiveness

In conclusion, veterinary antimicrobial susceptibility testing is at an inflection point characterized by technological advancement, shifting procurement dynamics, and heightened expectations for data-driven stewardship. The coexistence of phenotypic and molecular approaches offers complementary pathways to improve clinical decision-making and surveillance, while digital integration enhances the ability to transform isolated test results into longitudinal intelligence. However, challenges related to sample diversity, species-specific validation, and supply chain vulnerabilities remain salient and require coordinated responses from manufacturers, laboratories, and policy-makers.

Moving forward, success will depend on pragmatic strategies that align product innovation with the operational realities of diverse veterinary settings. Strengthening regional manufacturing, enhancing technical support, and deploying interoperable software solutions will reduce friction for end users and protect testing continuity in the face of fiscal and logistical pressures. Equally important is collaborative engagement across stakeholders to harmonize validation standards and ensure that diagnostic outputs are translated into effective antimicrobial stewardship actions that protect both animal and public health.

Ultimately, the diagnostic community has an opportunity to deliver measurable improvements in treatment outcomes and resistance containment by prioritizing accuracy, accessibility, and actionable data flows. By doing so, stakeholders can help secure the long-term effectiveness of antimicrobials and support resilient animal health systems that respond efficiently to evolving microbial threats.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid molecular diagnostics into on-farm veterinary AST workflows to reduce turnaround time
  • 5.2. Adoption of portable point-of-care antimicrobial susceptibility testing devices for livestock health management in remote farms
  • 5.3. Development of automated high-throughput phenotypic AST platforms designed specifically for veterinary bacterial isolates in clinical settings
  • 5.4. Implementation of artificial intelligence driven predictive analytics tools for monitoring antimicrobial resistance trends in animal health
  • 5.5. Expansion of multiplex PCR panels for simultaneous detection and quantification of multiple resistance genes in companion animal pathogens
  • 5.6. Emergence of personalized antimicrobial stewardship programs based on farm specific AST data to curb veterinary antibiotic misuse

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Antimicrobial Susceptibility Testing Market, by Test Type

  • 8.1. Automated Systems
    • 8.1.1. MicroScan Systems
    • 8.1.2. PHOENIX Systems
    • 8.1.3. VITEK Systems
    • 8.1.4. WalkAway Systems
  • 8.2. Broth Microdilution
    • 8.2.1. Automated Broth Microdilution
    • 8.2.2. Manual Broth Microdilution
  • 8.3. Disk Diffusion
  • 8.4. Etest
  • 8.5. Molecular Methods
    • 8.5.1. LAMP-Based Methods
    • 8.5.2. NGS-Based Methods
    • 8.5.3. PCR-Based Methods
    • 8.5.4. QPCR-Based Methods

9. Veterinary Antimicrobial Susceptibility Testing Market, by Animal Type

  • 9.1. Aquaculture
  • 9.2. Companion Animals
  • 9.3. Equine
  • 9.4. Livestock
  • 9.5. Poultry

10. Veterinary Antimicrobial Susceptibility Testing Market, by End User

  • 10.1. Pharma And Biotech
  • 10.2. Research Institutes
  • 10.3. Veterinary Diagnostic Laboratories
  • 10.4. Veterinary Hospitals And Clinics

11. Veterinary Antimicrobial Susceptibility Testing Market, by Pathogen Type

  • 11.1. Fungi
  • 11.2. Gram-Negative Bacteria
  • 11.3. Gram-Positive Bacteria
  • 11.4. Mycobacteria

12. Veterinary Antimicrobial Susceptibility Testing Market, by Sample Type

  • 12.1. Blood
  • 12.2. Milk
  • 12.3. Swab
  • 12.4. Tissue
  • 12.5. Urine

13. Veterinary Antimicrobial Susceptibility Testing Market, by Product Type

  • 13.1. Instruments
    • 13.1.1. Automated Instruments
    • 13.1.2. Bench-Top Instruments
  • 13.2. Kits And Reagents
    • 13.2.1. Consumables
    • 13.2.2. Reagents
  • 13.3. Software And Services
    • 13.3.1. Data Management Software
    • 13.3.2. Technical Support And Consulting

14. Veterinary Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. bioMerieux SA
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. IDEXX Laboratories, Inc.
    • 17.3.5. Bruker Corporation
    • 17.3.6. Creative Diagnostics
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Eurofins Scientific SE
    • 17.3.9. SGS SA
    • 17.3.10. Bio-Rad Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTIMICROBI